comparemela.com
Latest Breaking News On - Technology innovation model enterprise - Page 1 : comparemela.com
Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023
/PRNewswire/ From October 20 to 24, the 2023 ESMO Congress was held in Madrid, Spain. LX-039, an innovative anti-tumor drug developed by Luoxin.
China
Shanghai
Spain
Madrid
Chinese
Luoxin-pharma
National-torch-plan
Luoxin-pharmaceutical-group-stock-co-ltd
Clinical-cancer-research
Technology-innovation-model-enterprise
Fudan-university-shanghai-cancer-center
National-major-new-product-plan
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Chengdu
Sichuan
China
Taiwan
Shanghai
Hong-kong
Austria
Vienna
Wien
Macao
Macau-general
Macau
vimarsana © 2020. All Rights Reserved.